Trial · NCT02643381

Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial

NCT02643381, Phase 4, Completed, University of Texas Southwestern Medical Center; results first posted 2021-12-15

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial. Trials, record NCT02643381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02643381

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial
NCT number: NCT02643381
Status: Completed
Phases: Phase 4
Enrollment: 801 participants, actual
Lead sponsor: University of Texas Southwestern Medical Center
Conditions: Cardiopulmonary Arrest, Respiratory Arrest
Interventions: Etomidate, Ketamine, Emergency Endotracheal Intubation, Mechanical Ventilation
First posted: 2015-12-31
Last updated: 2021-12-15
Results first posted: 2021-12-15

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Survival at Day 7	Day 7	Survival is defined as the number of participants survived at day 7 following emergency endotracheal intubation
Secondary	Survival at Day 28	Day 28	Survival is defined as the number of participants survived at day 28 following emergency endotracheal intubation
Secondary	Sequential Organ Failure Assessment (SOFA) Scores	Day 1, Day 2, Day 3, Day 4	Sequential Organ Failure Assessment (SOFA) is a scoring system that assesses the performance of several organ systems. Possible scores range from 0 to 24. Higher score indicates higher degree of organ dysfunction
Secondary	Duration of Mechanical Ventilation	From time of documented insertion until the time of documented removal, assessed up to 28 days	Duration (in days) from insertion to removal of mechanical ventilation
Secondary	Duration of Catecholamine Therapy	From time of documented start of therapy until the time of documented end of therapy, assessed up to 28 days	Time (in days) from start to end of catecholamine therapy
Secondary	Length of Stay in ICU	Assessed up to 28 days	Length (in days) of ICU stay
Secondary	Number of Participants With New Diagnosis of Adrenal Insufficiency	Day 28	New diagnosis of adrenal insufficiency will be assessed by the the primary treating medical or surgical team via chart review
Secondary	Number of Attempts Necessary to Intubate	Immediate (Day 1)	This referrers to the number of documented intubation attempts necessary to intubate the patient.

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Survival at Day 7	Day 7		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Survival at Day 28	Day 28		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Sequential Organ Failure Assessment (SOFA) Scores	Day 1, Day 2, Day 3, Day 4		score on a scale	MEAN
SECONDARY	Duration of Mechanical Ventilation	From time of documented insertion until the time of documented removal, assessed up to 28 days		Days	MEDIAN
SECONDARY	Duration of Catecholamine Therapy	From time of documented start of therapy until the time of documented end of therapy, assessed up to 28 days		Days	MEDIAN
SECONDARY	Length of Stay in ICU	Assessed up to 28 days		Days	MEDIAN
SECONDARY	Number of Participants With New Diagnosis of Adrenal Insufficiency	Day 28		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Attempts Necessary to Intubate	Immediate (Day 1)	Clinical information incomplete or missing from 5 patients randomized to Etomidate and 6 patients randomized to Ketamine.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group28

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Survival at Day 7	Etomidate		306		Participants
Survival at Day 7	Ketamine		336		Participants
Survival at Day 28	Etomidate		254		Participants
Survival at Day 28	Ketamine		264		Participants
Sequential Organ Failure Assessment (SOFA) Scores	Etomidate	Day 1	10.7	Standard Deviation 4.6	score on a scale
Sequential Organ Failure Assessment (SOFA) Scores	Ketamine	Day 1	10.9	Standard Deviation 4.5	score on a scale
Sequential Organ Failure Assessment (SOFA) Scores	Etomidate	Day 2	9.8	Standard Deviation 5.1	score on a scale
Sequential Organ Failure Assessment (SOFA) Scores	Ketamine	Day 2	9.5	Standard Deviation 4.9	score on a scale
Sequential Organ Failure Assessment (SOFA) Scores	Etomidate	Day 3	8.4	Standard Deviation 5.3	score on a scale
Sequential Organ Failure Assessment (SOFA) Scores	Ketamine	Day 3	8.4	Standard Deviation 5.1	score on a scale

1 to 10 of 28Source ClinicalTrials.gov

See all 28 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Etomidate	400
Overall Study	STARTED	Ketamine	401
Overall Study	COMPLETED	Etomidate	396
Overall Study	COMPLETED	Ketamine	395
Overall Study	NOT COMPLETED	Etomidate	4
Overall Study	NOT COMPLETED	Ketamine	6

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Oral/ dental trauma	Injury, poisoning and procedural complications	Etomidate	2	396	2
serious	Oral/ dental trauma	Injury, poisoning and procedural complications	Ketamine	4	395	4
serious	Bleeding	Injury, poisoning and procedural complications	Etomidate	0	396	0
serious	Bleeding	Injury, poisoning and procedural complications	Ketamine	3	395	3
serious	Aspiration	Injury, poisoning and procedural complications	Etomidate	8	396	8
serious	Aspiration	Injury, poisoning and procedural complications	Ketamine	2	395	2

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Etomidate	142	396
Total, all-cause mortality	Ketamine	131	395
Total, other adverse events	Etomidate	0	396
Total, other adverse events	Ketamine	0	395
Total, serious adverse events	Etomidate	10	396
Total, serious adverse events	Ketamine	9	395

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29715485	RESULT	PubMed
34904190	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons5

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Etomidate vs Ketamine: Survival at Day 28	Trial comparisons
Etomidate vs Ketamine: Number of Participants With New Diagnosis of Adrenal Insufficiency	Trial comparisons
Etomidate vs Ketamine: Survival at Day 7	Trial comparisons
Etomidate vs Ketamine: deaths from any cause	Trial comparisons
Etomidate vs Ketamine: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02643381

GET https://conductscience.org/api/trials/v1/NCT02643381/results?page=2

API reference For AI assistants